Ubiquitin-specific protease 22: A novel molecular biomarker in cervical cancer prognosis and therapeutics

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 929-934

  Yang, Meng ^a   Liu, Yun Duo ^a   Wang, Yan Ying ^a   Liu, Tian Bo ^a   Ge, Ting Ting ^a   Lou, Ge ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Immunohistochemistry; Prognosis; Ubiquitin specific protease 22 (USP22)

Indexed keywords

BIOLOGICAL MARKER; DEUBIQUITINASE; KI 67 ANTIGEN; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOKING; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREGNANCY; PROGNOSIS; THIOLESTER HYDROLASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84899089765     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1121-4     Document Type: Article

References (39)

1. Jones SB. Cancer in the developing world: a call to action. BMJ. 1999;319:505-8. (Pubitemid 29391364)
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
3. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11-30.
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-36.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27. (Pubitemid 36159887)
6. Syrjanen K, Kataja V, YliskoskiM, Chang F, Syrjanen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol. 1992;79:675-82.
7. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110(3suppl2):S4-7.
8. Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28. (Pubitemid 46148088)
9. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458:438-44.
10. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM, et al. The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 2006;6:277-84.
11. Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikisresistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle. 2006;5:1208-16. (Pubitemid 43845382)
12. ZhaoY, LangG, Ito S, et al.ATFTC/STAGAmodulemediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008;29:92-101.
13. Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGAcomplex required for activated transcription and cell-cycle progression.Mol Cell. 2008;29:102-11.
14. Zhang XY, Pfeiffer HK, Thorne AW, et al. USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008;7:1522-4. (Pubitemid 351881314)
15. Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001;15:2042-7. (Pubitemid 32762047)
16. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004;4:143-53. (Pubitemid 38198742)
17. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92. (Pubitemid 46273572)
18. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008;26:2846-53.
19. Liu YL, Yang YM, Xu H, et al. Aberrant expression of USP22 is associated with liver metastasis and poor prognosis of colorectal cancer. J Surg Oncol. 2011;103:283-9.
20. Liu YL, Yang YM, Xu H, et al. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer. J Gastroenterol Hepatol. 2010;25:1800-5.
21. Zhang Y, Yao L, Zhang X, et al. Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol. 2011;137:1245-53.
22. Lv L, Xiao XY, Gu ZH, et al. Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem. 2011;346:11-21.
23. PijnappelWW, Timmers HT.Dubbing SAGAunveils newepigenetic crosstalk. Mol Cell. 2008;29:152-4.
24. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011;12:924-30.
25. Chipumuro E, Henriksen MA. The ubiquitin hydrolase USP22 contributes to 3′-end processing of JAK-STAT-inducible genes. FASEB J. 2012;26:842-54.
26. Liu YL, Jiang SX, Yang YM, et al. USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 2011;62:229-35.
27. Song H, Li C, Li R, Geng J. Prognostic significance of AEG-1 expression in colorectal carcinoma. Int J Colorectal Dis. 2010;25:1201-9.
28. Wu J, Zhou J, Yao L, Lang Y, Liang Y, Chen L, et al. High expression of M3 muscarinic acetylcholine receptor is a novel biomarker of poor prognostic in patients with non-small cell lung cancer. Tumor Biol. 2013. doi:10.1007/s13277- 013-0982-x.
29. Li C, Li Y, Wang X, Wang Z, Cai J, et al. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma. Histopathology. 2012;60:953-63.
30. Liang M, Li J, Wang D, Li S, Sun Y, Sun T, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China's Heilongjiang province. Tumor Biol. 2013. doi:10.1007/s13277-013-1006-6.
31. Li C, Cai J, Geng J, Li Y, Wang Z, Li R. Purification, characterization and anticancer activity of a polysaccharide from Panax ginseng. Int J Biol Macromol. 2012;51:968-73.
32. Cai J, Wu Y, Li C, Feng M, Shi Q, Li R, et al. Panax ginseng polysaccharide suppresses metastasis via modulating Twist expression in gastric cancer. Int J Biol Macromol. 2013;57:22-5.
33. Xin T, Zhang F, Jiang Q, Chen C, Huang D, et al. The inhibitory effect of a polysaccharide from Codonopsis pilosula on tumor growth and metastasis in vitro. Int J Biol Macromol. 2012;51:788-93.
34. Xin T, Zhang F, Jiang Q, Chen C, Huang D, et al. Extraction, purification and antitumor activity of a water-soluble polysaccharide from the roots of Polygala tenuifolia . Carbohydr Polym. 2012;90:1127-31.
35. Xin T, Zhang F, Jiang Q, Chen C, Huang D, et al. Purification and antitumor activity of two acidic polysaccharides from the roots of Polygala tenuifolia . Carbohydr Polym. 2012;90:1671-6.
36. Lin M, Xia B, Yang M, Gao S, Huo Y, Lou G. Characterization and antitumor activities of a polysaccharide from the rhizoma of Menispermum dauricum . Int J Biol Macromol. 2013;53:72-6.
37. Lin M, Xia B, Yang M, Gao S, Huo Y, Lou G. Anti-ovarian cancer potential of two acidic polysaccharides from the rhizoma of Menispermum dauricum . Carbohydr Polym. 2013;92:2212-7.
38. Kripke ML. Reducing death from cancer: what will it take? Tumor Biol. 2012;33:1275-8.
39. Zhu W, Pan X, Li F, Zhang Y, Lu X. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumor Biol. 2012;33:1653-9.